Trials / Terminated
TerminatedNCT04418297
A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy
A Randomized, Double-Blind, Placebo-Controlled, Sequential, Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Celltrion · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double-blind, placebo-controlled, sequential, 5-day treatment, ascending dose study in subjects with obstructive HCM aged 18-70 years. The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CT-G20.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CT-G20 | oral tablet |
| DRUG | Placebo | oral tablet |
Timeline
- Start date
- 2020-10-23
- Primary completion
- 2022-11-22
- Completion
- 2022-11-22
- First posted
- 2020-06-05
- Last updated
- 2023-03-02
Locations
11 sites across 3 countries: United States, Poland, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04418297. Inclusion in this directory is not an endorsement.